E Gustafsson1, E Litström1, C Berterö2, J Drott3,4. 1. Department of Surgery and Department of Medical and Health Sciences, Linköping University, 581 85, Linköping, Sweden. 2. Division of Nursing Science, Department of Medical and Health Sciences, Linköping University, 581 85, Linköping, Sweden. 3. Department of Surgery and Department of Medical and Health Sciences, Linköping University, 581 85, Linköping, Sweden. Jenny.Drott@liu.se. 4. Division of Nursing Science, Department of Medical and Health Sciences, Linköping University, 581 85, Linköping, Sweden. Jenny.Drott@liu.se.
Abstract
PURPOSE: The purpose of this study was to test the reliability of the Swedish version of the Oxaliplatin-Associated Neurotoxicity Questionnaire (OANQ) administrated throughout a self-reported mobile phone-based system, a pilot study. METHODS: Twenty-three patients from two university hospitals and two regional hospitals who had been treated with oxaliplatin were included through purposive sampling between autumn 2013 to autumn 2014. A test-retest was performed through a mobile phone-based system, with a recall period of 1 h to determine the reliability of the questionnaire. RESULTS: Internal consistency was strong for the three domains of the scale (α > 0.840). The statistical analyses for the test-retest indicated that the OANQ was stable. Intraclass correlation (ICC) for symptom items and effect on daily activities items showed an overall excellent reproducibility at 69 and 83 %, respectively. The weighted kappa for symptom items and daily activities items showed an overall almost perfect agreement at 59 and 52 %, respectively. A paired samples t test did not reveal any significant differences between the two measures. CONCLUSIONS: The OANQ was tested and considered a reliable assessment for capturing the oxaliplatin-induced peripheral neurotoxicity (OIPN) in patients receiving oxaliplatin. However, further reliability testing of the OANQ is needed.
PURPOSE: The purpose of this study was to test the reliability of the Swedish version of the Oxaliplatin-Associated Neurotoxicity Questionnaire (OANQ) administrated throughout a self-reported mobile phone-based system, a pilot study. METHODS: Twenty-three patients from two university hospitals and two regional hospitals who had been treated with oxaliplatin were included through purposive sampling between autumn 2013 to autumn 2014. A test-retest was performed through a mobile phone-based system, with a recall period of 1 h to determine the reliability of the questionnaire. RESULTS: Internal consistency was strong for the three domains of the scale (α > 0.840). The statistical analyses for the test-retest indicated that the OANQ was stable. Intraclass correlation (ICC) for symptom items and effect on daily activities items showed an overall excellent reproducibility at 69 and 83 %, respectively. The weighted kappa for symptom items and daily activities items showed an overall almost perfect agreement at 59 and 52 %, respectively. A paired samples t test did not reveal any significant differences between the two measures. CONCLUSIONS: The OANQ was tested and considered a reliable assessment for capturing the oxaliplatin-induced peripheral neurotoxicity (OIPN) in patients receiving oxaliplatin. However, further reliability testing of the OANQ is needed.
Authors: Patricia A Ganz; Stephanie R Land; Cynthia Antonio; Ping Zheng; Greg Yothers; Laura Petersen; D Lawrence Wickerham; N Wolmark; Clifford Y Ko Journal: J Cancer Surviv Date: 2009-06-13 Impact factor: 4.442
Authors: Christine Paul; Ryan Courtney; Rob Sanson-Fisher; Mariko Carey; David Hill; Jody Simmons; Shiho Rose Journal: BMC Med Res Methodol Date: 2014-04-01 Impact factor: 4.615
Authors: Tiffany Li; Susanna B Park; Eva Battaglini; Madeleine T King; Matthew C Kiernan; David Goldstein; Claudia Rutherford Journal: Qual Life Res Date: 2022-05-21 Impact factor: 3.440